跳至主要内容
临床试验/ISRCTN84460768
ISRCTN84460768已完成不适用

Effect of additional single or repeated dosage of Kappaproct® to corticosteroid treated patients with brain oedema caused by brain tumour: a multicentre open one-arm non-randomised trial

InDex Pharmaceutials AB (Sweden)0 个研究点目标入组 30 人开始时间: 2009年12月2日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Adult men and women (greater than 18 year) with malignant brain oedema confirmed by MRI/computed tomography (CT), caused by malignant glioma, menigioma or metastatic disease (histological and/or cytological verified)
  • 2. World Health Organization (WHO)/Eastern Cooperative Oncology Group (ECOG) performance 0 - 3
  • 3. Betapred® (betamethasone) dose 8 mg x 2 for more than 24 hours
  • 4. Clinical need for increase of corticosteroid dosage
  • 5. Possibility to perform repeated MRI examinations

排除标准

  • 1. History and precence of a clinical significant cardiovascular, hepatic, haematological, endocrine, neurological and psychiatric disease or immune compromised state as judged by the investigator
  • 2. Chemotherapy that has been administrated within 4 weeks prior to inclusion
  • 3. Positive urine pregnancy test in women at enrolment
  • 4. Intake of drug under investigation

研究者

发起方
InDex Pharmaceutials AB (Sweden)

相似试验